FDA Approves Kadcyla for HER2-Positive, Late-Stage Breast Cancer

by Kathy Jones on  February 23, 2013 at 6:56 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

The US Food and Drug Administration has approved a new therapy developed by Roche which it hopes will prove beneficial for patients suffering from HER2-positive, late-stage breast cancer.
 FDA Approves Kadcyla for HER2-Positive, Late-Stage Breast Cancer
FDA Approves Kadcyla for HER2-Positive, Late-Stage Breast Cancer

The therapy, known as Kadcyla, has been approved for patients who have already been treated with another anti-HER2 therapy, trastuzumab, along with chemotherapy drug, taxanes. "Kadcyla delivers the drug to the cancer site to shrink the tumor, slow disease progression and prolong survival", FDA's Dr Richard Pazdur said.

The FDA revealed that clinical trials conducted on a group of 991 patients should that Kadcyla increased the progression free survival period to 9.6 months compared to 6.4 months in patients treated with lapatinib plus capecitabine while the overall survival period was 30.9 months compared to 25.1 months.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Women and Cancer Breast Biopsy Pagets disease of the breast Mastitis Cancer and Homeopathy Breast Cancer Facts Cancer Facts Cancer Tattoos A Body Art Breasts - Structures and Types 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

Advertisement

News Category

News Archive